High risk of zika virus triggered Guillain-Barre syndrome in older children fuels the demand.

Dubai, United Arab Emirates - June 7, 2021 /MarketersMedia/ —

The global zika virus testing market is forecast to grow at moderate pace throughout the forecast period of 2021 to 2031. According to a study by Future Market Insights (FMI), the surging demand for accurate zika virus testing is one of the key factors driving the market growth.

Frequent outbreaks of viral pandemic and epidemic in the last few years have pushed diagnostic testing developments into new dimensions. Clinicians and healthcare experts are working towards developing advanced, precise, and sophisticated testing solutions amidst these threats.

To Get Sample Copy of Report Visit @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2913

Growing inclination towards enzyme-linked immunosorbent (ELISA) and IgG/IgA testing mechanisms in zika virus testing due to its high accuracy and low turnaround time will promote the market growth, finds ESOMAR-certified consulting firm Future Market Insights in this study.

Major players in zika virus testing are looking forward to collaborate with leading research institutes and government agencies to boost the R&D of new testing methods.

Government initiatives to curb the virus’s spread have resulted in proliferation of awareness campaigns. These initiatives are accelerating the frequency of infection diagnostics and testing. This will boost the market growth.

For instance, in 2017, the New Mexico Department of Health (NMDOH) announced the launch of a summer campaign intended at educating pregnant women and their partners, who might be considering visiting places affected by Zika virus, about the risk of the virus and potential for transmission.

As zika virus epidemic subsided, the requirement for testing declined in response. Government also reduced their efforts on discovering new testing and treatment option for future use.

However, the COVID-19 pandemic reignited the growth prospects as the individuals are mandated to screen for any viral strain presence as a precautionary measure.

“Clinical studies have showed that zika virus infection during pregnancy leads to microcephaly and other severe fetal brain defects. Increasing laboratory testing for early detection of infection in women will boost the market growth,” opined a FMI analyst. 

For More Details, Ask Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-2913

Key Takeaways

Commercialization of zika virus testing and administration of various regulatory approaches to assist active viral case load testing will boost the zika virus testing market in the U.S.
Brazil was the focal point of first zika virus epidemic outbreak. Government initiated a massive nationwide undertaking to demolish potential mosquito breeding sites and educate the public about their role in combating spread of the disease. These strategies created an ideal environment for market growth.
Administration of regular diagnostic tests to check for any virus and collaboration between various healthcare agencies to eradicate the zika virus drives the market growth in Puerto Rico.
The U.K. is anticipated to offer lucrative growth opportunities for zika virus testing market due to the implementation of strict government regulations regarding infection testing, two weeks prior to leaving the country.
High accuracy and reliability of ELISA zika virus test coupled with cost effectiveness and no use of radioisotopes will drive the market growth during the forecast period.

Prominent Drivers

Elevated demand for various serological tests in temperate regions due to rising tourism in tropical countries and increasing concern regarding epidemic outbreak will magnify the market growth.
Studies have confirmed the possibility of zika virus being passed on by a pregnant women to her fetus. This could result in severe fetal brain defects. Hence demand for zika virus testing is quite high among pregnant women, especially in affected places.

Key Restraints

Limited efficiency of zika virus testing in delivering accurate and fast results is restricting the market growth.
Restricted growth opportunities due to confinement of zika virus cases in tropical regions, hinders the market demand.
Increasing cross reactivity of zika virus with other more prevalent viruses like flavivirus and dengue decelerates the market growth.

Download Methodology of this Report @ https://www.futuremarketinsights.com/askus/rep-gb-2913

Competitive Landscape

Time is of great essence while offering the proper diagnosis especially for zika virus. Key market leaders are working on utilizing advance testing methods to improve the turn-around time and rapid results.

Such approach assists physician to design accurate treatment for infected patients. Collaboration is necessary between research and testing institute and drug manufacturers for faster market expansion. Strategic collaborations also are identified as key strategies adopted by market players.

For instance:

EUROIMMUN US is a global leader in zika virus testing. It offers anti-zika virus test “ELISA” and indirect immunofluorescence test (IFA) formats, both permits the quick detection of specific antibodies (IgM and IgG) in the blood of those who may be infected.

EUROIMMUN US joined hands with Roche Diagnostics on optional agreement basis in 2017. The agreement allowed Roche Diagnostics to access intellectual property in zika virus immunodiagnostics assigned to EUROIMMUN.

Creative Diagnostics introduced zika virus testing called the Recombinant Zika Virus Envelope protein test which contains Histidine tags. The testing has purity score ranks above 85% and are available in 1 mg vials. Creative Diagnostics also provides the Recombinant Zika Virus NS1 protein test.

DiaSorin S.p.A. signed and agreed to acquire Luminex Corporation in 2021. As per the Luminex, this transaction will assist both companies to gain access to broader assay portfolios, developed research tools and expanded support services. This collaboration will also promote new partnerships in the biopharmaceutical, academic and clinical spaces.

Leading players profiled by FMI operating in zika virus testing market include:

EUROIMMUN US Inc.
Creative Diagnostics
Quest Diagnostics
Artron Laboratories Inc.
RapiGEN Inc.
GenBody Inc.
JAJ International Inc.
LumiQuick Diagnostics Inc.
Biocan Diagnostics Inc.
NECTAR LIFESCIENCES LTD.
Luminex Corporation
ARUP Laboratories
Abbott Molecular Inc.
Hologic
Vela Diagnostics

More Insights on FMI’s Zika Virus Testing Market

The latest market study on global zika virus testing market by Future Market Insights gives a detailed segmentation for the forecast period of 2021-2031. In order to gain a better perspective of the global market potential, its growth, trends, and opportunities, the market is segmented on the basis of:

Test Type

Rapid IgG/IgM Test
ELISA Test

End-User

Hospitals & Clinics
Private Commercial Laboratories
Government/Publicly Funded Programs

Region

North America & Europe (US, UK, Germany, Spain, France, Italy and Rest of Europe)
Latin America (Brazil, Mexico, Colombia  and Rest of LATAM)
Central America (Costa Rica, Nicaragua, Guatemala and Rest of Central America)
Caribbean (Puerto Rico and Rest of the Caribbean)
South East Asia (Thailand, Singapore, Vietnam and Rest of South East Asia)
Rest of the World (North Africa and South Africa)

Contact Info:
Name: Abhishek Budholiya
Email: Send Email
Organization: Future Market Insights
Website: https://www.futuremarketinsights.com/reports/zika-virus-testing-market

Source URL: https://marketersmedia.com/demand-for-greater-accuracy-and-timely-zika-virus-diagnosis-propelling-zika-virus-testing-market-growth-fmi/89025025

Source: MarketersMedia

Release ID: 89025025